• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

    2/13/23 3:25:03 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care
    Get the next $PSTV alert in real time by email
    SC 13G/A 1 d9929592_13g-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Plus Therapeutics Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    72941H400
    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     


    CUSIP No
    72941H400    

     

    1. NAME OF REPORTING PERSONS  
         
      Parkman Healthcare Partners LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      583,467  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      583,467  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      583,467  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      1.7%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, IA

     

     

     
     

     

     


    CUSIP No
    72941H400  

     

    1. NAME OF REPORTING PERSONS  
         
      Parkman Healthcare Partners Holdings LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      583,467  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      583,467  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      583,467  
         
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    [_]

     
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      1.7%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     
     

     

     


    CUSIP No
    72941H400  

     

    1. NAME OF REPORTING PERSONS  
         
      Parkman Healthcare Partners Holdings GP LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
         
        (a)  [_]
        (b)  [X]
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      583,467  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      583,467  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      583,467  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
      [_]  
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      1.7%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     
     

     

     


    CUSIP No
    72941H400    

     

    1. NAME OF REPORTING PERSONS  
         
      Gregory Martinez  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      583,467  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      583,467  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      583,467  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      1.7%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN

     

     

     
     

     

     


    CUSIP No
    72941H400    

     

    Item 1. (a). Name of Issuer:  
           
        Plus Therapeutics, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    4200 Marathon Boulevard, Suite 200

    Austin, Texas 78756

    United States of America

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Parkman Healthcare Partners LLC

    Parkman Healthcare Partners Holdings LP

    Parkman Healthcare Partners Holdings GP LLC

    Gregory Martinez

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Parkman Healthcare Partners LLC

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A.

     

    Parkman Healthcare Partners Holdings LP

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A.

     

    Parkman Healthcare Partners Holdings GP LLC

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A.

     

    Gregory Martinez

    c/o Parkman Healthcare Partners LLC

    700 Canal Street, 2nd Floor,

    Stamford, Connecticut 06902, U.S.A.

     

     

     

      (c). Citizenship:  
           
       

    Parkman Healthcare Partners LLC – Delaware

    Parkman Healthcare Partners Holdings LP – Delaware

    Parkman Healthcare Partners Holdings GP LLC – Delaware

    Gregory Martinez– United States

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  

     

      (e). CUSIP Number:  
           
        72941H400  

     

     

     
     

     

     


    Item 3.
    If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    583,467 shares deemed beneficially owned by Parkman Healthcare Partners LLC

    583,467 shares deemed beneficially owned by Parkman Healthcare Partners Holdings LP

    583,467 shares deemed beneficially owned by Parkman Healthcare Partners Holdings GP LLC

    583,467 shares deemed beneficially owned by Gregory Martinez

     

      (b)   Percent of class:
         
       

    1.7% deemed beneficially owned by Parkman Healthcare Partners LLC

    1.7% deemed beneficially owned by Parkman Healthcare Partners Holdings LP

    1.7% deemed beneficially owned by Parkman Healthcare Partners Holdings GP LLC

    1.7% deemed beneficially owned by Gregory Martinez

     

     
     

     

     

      (c)   Number of shares as to which Parkman Healthcare Partners LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 583,467 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 583,467 .

     

      Number of shares as to which Parkman Healthcare Partners Holdings LP has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 583,467 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 583,467 .

     

      Number of shares as to which Parkman Healthcare Partners Holdings GP LLC has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 583,467 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 583,467 .
       
      Number of shares as to which Gregory Martinez has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 583,467 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 583,467 .

     

     
     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
       

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

    The shares of the Issuer reported herein are owned by advisory clients or funds managed by Parkman Healthcare Partners LLC and/or its related persons’ accounts.

       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A

     


    Item 8.
    Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        February 13, 2023
        Date
         
      Parkman Healthcare Partners LLC *
         
           
        By: /s/ Gregory Martinez
        Name: Gregory Martinez
        Title: Managing Member
           
           
      PARKMAN HEALTHCARE PARTNERS HOLDINGS LP*
           
           
        By: /s/ Gregory Martinez
        Name: Gregory Martinez
        Title: Managing Member
           
           
      PARKMAN HEALTHCARE PARTNERS HOLDINGS GP LLC*
           
           
        By: /s/ Gregory Martinez
        Name: Gregory Martinez
        Title: Managing Member
           
           
      GREGORY MARTINEZ*
           
           
        By: /s/ Gregory Martinez
        Name: Gregory Martinez
           

     

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated February 13, 2023 relating to the Common Stock, par value $0.001 per share of Plus Therapeutics, Inc., shall be filed on behalf of the undersigned.

     

        February 13, 2023
        Date
         
      Parkman Healthcare Partners LLC
         
           
        By: s/ Gregory Martinez
        Name: Gregory Martinez
        Title: Managing Member
           
           
      PARKMAN HEALTHCARE PARTNERS HOLDINGS LP
           
           
        By: /s/ Gregory Martinez
        Name: Gregory Martinez
        Title: Managing Member
           
           
      PARKMAN HEALTHCARE PARTNERS HOLDINGS GP LLC
           
           
        By: /s/ Gregory Martinez
        Name: Gregory Martinez
        Title: Managing Member
           
           
      GREGORY MARTINEZ
           
           
        By: /s/ Gregory Martinez
        Name: Gregory Martinez
           
           

     

    Get the next $PSTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTV

    DatePrice TargetRatingAnalyst
    3/17/2025$9.00Buy
    D. Boral Capital
    More analyst ratings

    $PSTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hawkins Richard J bought $5,996 worth of shares (4,000 units at $1.50), increasing direct ownership by 36% to 15,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/17/24 7:00:04 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Hawkins Richard J bought $8,512 worth of shares (6,285 units at $1.35), increasing direct ownership by 128% to 11,188 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/16/24 7:00:03 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Director Petersen Greg bought $16,875 worth of shares (12,500 units at $1.35), increasing direct ownership by 34% to 48,921 units (SEC Form 4)

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      9/13/24 6:04:12 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

      HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

      4/23/25 8:00:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

      AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer. Dr. Rosol will lead the company's clinical, pre-clinical, and biomarker development activities. "Plus is at an inflection point in our clinical development as we move from mid-stage to pivotal trials next year," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Mike's background in oncology and radiotherapeutic

      2/20/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

      Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance payment for leptomeningeal cancer targeted radiotherapeutic development program AUSTIN, Texas, June 07, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Dr. Greg Fuller a

      6/7/24 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Plus Therapeutics with a new price target

      D. Boral Capital initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $9.00

      3/17/25 7:41:57 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright initiated coverage on Plus Therapeutics

      HC Wainwright initiated coverage of Plus Therapeutics with a rating of Buy

      2/11/21 7:44:56 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Plus Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $7.00

      2/11/21 6:52:36 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clowes Howard

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:10 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Hawkins Richard J

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:11 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Petersen Greg

      4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

      2/20/25 5:30:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    SEC Filings

    See more
    • PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      6/20/25 4:16:26 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form S-1/A filed by PLUS THERAPEUTICS Inc.

      S-1/A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      6/18/25 9:51:02 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-1 filed by PLUS THERAPEUTICS Inc.

      S-1 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

      6/17/25 9:21:53 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

      Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2025, and provides an overview of recent and upcoming business highlights. "We improved our cash position in the first quarter as a result of both a financing and grant support," said Marc H. Hedrick, M.D., Plus Therapeutics President

      5/30/25 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

      HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company") today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the "Quarterly Report"). The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's securities on Nasdaq. Nasdaq has

      5/23/25 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

      Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology Conference HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the presentation of new data on its lead drug REYOBIQ™ (rhenium Re186 obisbemeda) during both an oral presentation and a poster presented at the Nuclear Medicine and

      5/14/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLUS THERAPEUTICS Inc.

      SC 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      6/5/24 7:26:01 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/13/23 3:25:03 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by PLUS THERAPEUTICS Inc. (Amendment)

      SC 13G/A - PLUS THERAPEUTICS, INC. (0001095981) (Subject)

      2/11/22 7:53:23 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care

    $PSTV
    Financials

    Live finance-specific insights

    See more
    • Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "The rece

      3/27/25 4:05:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

      HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. Webcast and Conference Call Date/Time:Thursday, March 27, 2025 @ 5:00 PM ETWebcast:https://edge.media-server.com/mmc/p/5r5hkcqqDial-in

      3/19/25 7:30:00 AM ET
      $PSTV
      Medical/Dental Instruments
      Health Care
    • Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) ca

      11/14/24 4:15:00 PM ET
      $PSTV
      Medical/Dental Instruments
      Health Care